Abstract: CVS Health posted solid first-quarter results driven by a strong medical-insurance margin, leading to an elevated fair-value estimate and raised guidance. While still no moat, margin improvements and a lower-than-expected Medicare Advantage settlement mitigate risk despite ongoing regulatory uncertainty.Summary: CVS Health posted solid Q1 growth led by rising adjusted earnings and a stronger Medicare Advantage margin, prompting a higher fair value despite no moat and ongoing regulatory risk.

ForkLibertarian

2026-05-12 19:24:20

Abstract generation in progress

Key Morningstar Metrics for CVS Health

Fair Value Estimate

: $105.00
Morningstar Rating

: ★★★★
Morningstar Economic Moat Rating

: None
Morningstar Uncertainty Rating

: High

What We Thought of CVS Health’s Earnings

CVS Health CVS reported first-quarter results that included 6% revenue growth, 12% adjusted operating income growth, and adjusted EPS growth of 14%. Management also raised its full-year guidance. Shares rallied over 6% in midday trading on May 6 on this news.

Why it matters: Margin improvement in the medical insurance operations is materially boosting profits and cash flows at CVS at an even faster pace than management expected a quarter ago.

The medical insurance operations delivered 53% adjusted operating profit growth in the quarter, primarily due to a 270-basis-point improvement in its medical cost ratio on better performance in its government-sponsored programs and exiting the challenging individual exchange business.
While its other major segments were a drag on profit growth in the quarter, that medical insurance margin improvement was enough for management to boost its 2026 outlook for adjusted EPS to $7.30-$7.50 from $7.00-$7.20 and operating cash flow to at least $9.5 billion from at least $9.0 billion.

The bottom line: We are raising our fair value estimate to $105 per share from $97 to reflect these improving 2026 margins, a recent Medicare Advantage settlement that was lower than we expected, and cash flows generated since our last valuation change. Shares remain in moderately undervalued territory.

However, even considering ongoing efforts to increase margins, our no-moat rating on CVS reflects weak economic profitability expected through the next few years, although CVS does look on the strong end of that rating’s spectrum.
Also, we continue to see elevated regulatory risk at CVS, reflected in our High Uncertainty Rating, although a recent MA risk assessment settlement and pharmacy benefit manager business model changes to improve transparency are mitigating some of these risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.